

# OPIOID ANALYTICS

In response to the nationwide epidemic, The Lewin Group offers expertise in analyzing prevalence, impacts and trends with opioid utilization. We do this via a multi-tier approach using actual opioid claims data along with advanced data-visualization techniques that allow users to easily analyze different factors that impact opioid use.

#### **OVERVIEW**

Based on findings from the National Institute of Health, more than 90 Americans die every day from an opioid overdose. The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse alone in the United States is \$78.5 billion a year. This includes the costs of health care, lost productivity, addiction treatment and criminal justice involvement. Initiatives for solving this crisis should start with a thorough review of the data in order to identify key drivers.

#### **SERVICES**

The Lewin Group provides data intake, validation and enhancement to produce data visualizations that illustrate opioid trends and provide drill-down analysis to potential factors that drive them. This informs strategy, identifies who should be engaged and drives action for government agencies, payers and providers. We provide the following analytics:

**Population analytics** visualize trends, geographies and opioid utilization patterns. This includes analysis of opioid use by geographic area and disease condition as well as concurrent opioid use from multiple providers.

**Provider/pharmacy analytics** show physician prescribing patterns and pharmacy point-of-sale claims. This includes analysis of opioid prescribing by provider specialty and providers with high rates of opioid prescriptions.

**Individual/patient analytics** evaluate characteristics of patients with high levels of opioid utilization, including those with multiple prescribing providers and pharmacies.

### **EXAMPLES OF ANALYSIS INCLUDE:**

# Opioid use by county

HealthView provides graphical visualizations of data with drill-down capabilities to allow for analysis of key utilization drivers. The graphic represents the State of Georgia, but a similar map can be built for any state. This allows drill-down to the county level and shows the total number of opioid prescriptions, as illustrated by the size and color of the dot, and the percentage of members with an opioid prescription, as illustrated by the color. By clicking on a county, other dimensions, such as age and eligibility group, and other measures, such as prescriptions per member, are available.



# Pharmacy quality alliance measures

This graphic shows multiple measures developed by the Pharmacy Quality Alliance to study medication safety and adherence specific to opioids. By clicking on a measure, the user can analyze that measure across different dimensions, such as demographic factors and the presence of mental health and substance abuse conditions. Each measure can also be shown in a state map and analyzed by county.

| Measure   | Measure description  |
|---|--|
| Use of opioids<br>from multiple<br>providers                | The proportion of individuals with two or more opioid prescriptions for opioids from for o more prescribers AND four or more pharmacies.   |
| Use of opioids at<br>high dosage                            | The proportion of individuals with two or more opioid prescriptions with a daily dosage greater than 120 morphine milligram equivalents for 90 consecutive days or longer.   |
| Use of opioids at<br>high dosage from<br>multiple providers | The proportion of individuals with two or more opioid prescriptions with a daily dosage greater than 120 morphine milligram equivalents for 90 consecutive days or longer AND two or more prescriptions for opioids from four or more prescribers AND four or more pharmacies. |
| Concurrent use of opioids and benzodiazepines               | This measure examines the percentage of individuals 18 years and older with concurrent use of prescription opioids and benzodiazepines for 30 or more cumulative days.   |
| Usage rates   |  |
|   | 12.94%   |
| 7.30%   | 5.31%  |
|   | 1.54%  |

### **ABOUT US**

Use of opioids

from multiple

providers

The Lewin Group is a premier national health care and human services consulting firm with nearly 50 years of experience finding answers and solving problems for leading organizations in the public, nonprofit and private sectors. We understand the industry and provide our clients with high-quality products and insightful support to help them maximize the delivery of programs and services that make a difference in the lives of their constituents.

**The Lewin Group** | Health care and human services policy research and consulting | **www.lewin.com** 3130 Fairview Park Drive, Suite 500 • Falls Church, VA • 22042 From North America, call toll free: 1-877-227-5042 • inquiry@lewin.com

Use of opioid at

high dosage

The Lewin Group is an Optum Company. Optum, a wholly-owned subsidiary of UnitedHealth Group, was founded in 1996 to develop, acquire and integrate the world's best-in-class health care information technology capabilities. For more information, visit www.optum.com. The Lewin Group operates with editorial independence and provides its clients with the very best expert and impartial health care and human services policy research and consulting services. Visit www.lewin.com for more information. The Lewin Group and logo, Optum and the Optum logo are registered trademarks of Optum. All other brand or product names are trademarks or registered marks of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer. © 2018 Optum. All rights reserved. WF495818 06/18

Use of opioid at

high dosage from

multiple providers

Concurrent use

of opioids and

benzodiazepines